{
    "clinical_study": {
        "@rank": "92563", 
        "arm_group": {
            "arm_group_label": "symptoms of liver disease", 
            "description": "Device: Samsung LABGEO PT10 Hepatic Panel"
        }, 
        "biospec_descr": {
            "textblock": "Retaining serum and plasma specimens"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "To establish the performance characteristics of the Samsung LABGEO PT10 by comparing the\n      test results of the PT10 Hepatic assay with results obtained from an FDA-cleared chemistry\n      analyzer."
        }, 
        "brief_title": "Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Disease, Healthy", 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "detailed_description": {
            "textblock": "To establish the correlation between measurand values  as obtained from the Samsung LABGEO\n      PT10 Hepatic Panel at the point of care, and the corresponding measurand values as obtained\n      on a commercial clinical chemistry analyzer, with respect to prospectively collected human\n      serum specimens."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or  female subjects with a history of elevated liver enzymes or symptoms\n             suggestive of elevated liver enzymes\n\n          -  Presenting to the site and requiring testing for levels of liver enzymes as part of\n             routine care at the site\n\n          -  Subjects able and willing to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Subjects unable or unwilling to provide written informed consent\n\n          -  Subjects with a life-threatening disease or any serious, potentially life-threatening\n             medical illness that may compromise patient safety or study conduct"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Primary care clinics"
            }
        }, 
        "enrollment": {
            "#text": "440", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104154", 
            "org_study_id": "T10-02"
        }, 
        "intervention": {
            "arm_group_label": "symptoms of liver disease", 
            "intervention_name": "Samsung LABGEO PT10 Hepatic Panel", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Portland", 
                    "country": "United States", 
                    "state": "Oregon", 
                    "zip": "97239"
                }, 
                "name": "Oregon Health & Science University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting", 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Bias between Samsung LABGEO PT10 serum results and matching FDA-cleared comparator assay", 
            "safety_issue": "No", 
            "time_frame": "baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104154"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean percentage difference between all pairs of plasma and serum measurements using Bland-Altman plot of differences.", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "Standard deviation and coefficients of variation of between run, between day and total precision.", 
                "safety_issue": "No", 
                "time_frame": "20 days"
            }, 
            {
                "measure": "Estimates of reference intervals by computing  the 2.5th percentile of associated distribution of test measurement (for each analyte) and the 97.5th percentile of associated distribution.", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "Mean percentage difference between all pairs of serum and whole blood measurements using Bland-Altman plot of differences.", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "Mean percentage difference between all pairs of plasma and whole blood measurements using Bland-Altman plot of differences.", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }
        ], 
        "source": "Samsung Electronics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Electronics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014", 
        "why_stopped": "To conduct interim analysis and assess whether assay changes are recommended."
    }
}